PROCEPT BioRobotics (NASDAQ:PRCT) Shares Down 4.8% – What’s Next?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT)’s share price dropped 4.8% during mid-day trading on Wednesday . The company traded as low as $21.82 and last traded at $21.7910. Approximately 45,548 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,611,013 shares. The stock had previously closed at $22.89.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: CEO Larry Wood purchased 23,900 PRCT shares at an average price of $20.85, investing approximately $498,315. The open-market purchase may signal that management views the stock as undervalued. SEC Form 4 filing
• Neutral Sentiment: Several firms reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status in the proposed class action. The notices are largely procedural and do not constitute new company disclosures, although they keep the litigation in focus. The covered purchase period is February 28, 2024, through February 25, 2026. Class action deadline notice
• Negative Sentiment: The lawsuit alleges that PROCEPT and certain executives made false or misleading statements regarding handpiece demand and sales, procedure volumes and excess customer inventory created by repeated late-quarter bulk discounts. Potential consequences include legal costs, reputational damage and greater uncertainty about the company’s sales trajectory. Former Chief Commercial Officer Hisham Shiblaq was also identified as a secondary defendant. Levi and Korsinsky lawsuit notice
• Negative Sentiment: Recent quarterly results showed mixed fundamentals: revenue rose 19.3% year over year to $94.5 million and exceeded estimates, but the company posted a $0.47 per-share loss, slightly worse than expected. PROCEPT remains unprofitable, with analysts forecasting a full-year loss. Q2 2026 earnings call transcript

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PRCT shares. Evercore set a $23.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. William Blair cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Truist Financial set a $21.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Wall Street Zen raised shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Jefferies Financial Group restated a “hold” rating and set a $20.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.00.

PROCEPT BioRobotics Stock Performance

The stock has a market capitalization of $1.23 billion, a P/E ratio of -11.07 and a beta of 0.89. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $21.39 and a two-hundred day moving average price of $24.63.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The firm had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. PROCEPT BioRobotics’s revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.35) EPS. Equities analysts expect that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Larry L. Wood purchased 23,900 shares of PROCEPT BioRobotics stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On PROCEPT BioRobotics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in shares of PROCEPT BioRobotics in the 2nd quarter valued at about $109,961,000. Prosight Management LP grew its holdings in shares of PROCEPT BioRobotics by 1,692.4% during the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after purchasing an additional 1,303,009 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after purchasing an additional 1,262,928 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares during the last quarter. Finally, William Blair Investment Management LLC bought a new position in shares of PROCEPT BioRobotics in the second quarter worth approximately $16,020,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.